vs
AIR LEASE CORP（AL）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是AIR LEASE CORP的1.4倍（$197.9M vs $140.8M），AIR LEASE CORP净利率更高（128.5% vs 6.7%，领先121.8%），AIR LEASE CORP同比增速更快（90.4% vs 13.6%），AIR LEASE CORP自由现金流更多（$342.1M vs $17.6M），过去两年AIR LEASE CORP的营收复合增速更高（69.6% vs 14.4%）
航空租赁公司（ALC）是2010年成立的美国飞机租赁企业，由史蒂文·F·乌德瓦-哈齐执掌运营。公司直接向波音、空客、巴航工业、ATR采购全新商用飞机，为全球各地航空公司客户提供专业的飞机租赁及融资服务。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AL vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.4倍
$140.8M
营收增速更快
AL
高出76.8%
13.6%
净利率更高
AL
高出121.8%
6.7%
自由现金流更多
AL
多$324.6M
$17.6M
两年增速更快
AL
近两年复合增速
14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.8M | $197.9M |
| 净利润 | $180.9M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | 128.5% | 6.7% |
| 营收同比 | 90.4% | 13.6% |
| 净利润同比 | 60.2% | 143.9% |
| 每股收益（稀释后） | $1.49 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALRGEN
| Q4 25 | $140.8M | $197.9M | ||
| Q3 25 | $44.5M | $188.8M | ||
| Q2 25 | $53.0M | $182.4M | ||
| Q1 25 | $92.9M | $169.2M | ||
| Q4 24 | $74.0M | $174.1M | ||
| Q3 24 | $65.0M | $154.9M | ||
| Q2 24 | $57.8M | $154.1M | ||
| Q1 24 | $49.0M | $151.3M |
净利润ALRGEN
| Q4 25 | $180.9M | $13.3M | ||
| Q3 25 | $146.5M | $14.9M | ||
| Q2 25 | $385.2M | $14.9M | ||
| Q1 25 | $375.8M | $5.8M | ||
| Q4 24 | $112.9M | $-30.3M | ||
| Q3 24 | $104.0M | $-654.0K | ||
| Q2 24 | $102.9M | $3.3M | ||
| Q1 24 | $107.9M | $2.1M |
毛利率ALRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率ALRGEN
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.3% |
净利率ALRGEN
| Q4 25 | 128.5% | 6.7% | ||
| Q3 25 | 329.2% | 7.9% | ||
| Q2 25 | 726.9% | 8.2% | ||
| Q1 25 | 404.5% | 3.4% | ||
| Q4 24 | 152.7% | -17.4% | ||
| Q3 24 | 160.0% | -0.4% | ||
| Q2 24 | 178.2% | 2.2% | ||
| Q1 24 | 220.2% | 1.4% |
每股收益（稀释后）ALRGEN
| Q4 25 | $1.49 | $0.24 | ||
| Q3 25 | $1.21 | $0.26 | ||
| Q2 25 | $3.33 | $0.26 | ||
| Q1 25 | $3.26 | $0.10 | ||
| Q4 24 | $0.83 | $-0.55 | ||
| Q3 24 | $0.82 | $-0.01 | ||
| Q2 24 | $0.81 | $0.06 | ||
| Q1 24 | $0.87 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.4M | $767.6M |
| 总债务越低越好 | $19.7B | $542.2M |
| 股东权益账面价值 | $8.5B | $2.1B |
| 总资产 | $32.9B | $2.9B |
| 负债/权益比越低杠杆越低 | 2.33× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ALRGEN
| Q4 25 | $466.4M | $767.6M | ||
| Q3 25 | $452.2M | $748.7M | ||
| Q2 25 | $454.8M | $708.9M | ||
| Q1 25 | $456.6M | $697.2M | ||
| Q4 24 | $472.6M | $757.4M | ||
| Q3 24 | $460.8M | $784.0M | ||
| Q2 24 | $454.1M | $809.1M | ||
| Q1 24 | $554.4M | $780.6M |
总债务ALRGEN
| Q4 25 | $19.7B | $542.2M | ||
| Q3 25 | $20.2B | $537.9M | ||
| Q2 25 | $20.3B | — | ||
| Q1 25 | $19.9B | — | ||
| Q4 24 | $20.2B | $525.6M | ||
| Q3 24 | $20.2B | — | ||
| Q2 24 | $19.7B | — | ||
| Q1 24 | $19.5B | — |
股东权益ALRGEN
| Q4 25 | $8.5B | $2.1B | ||
| Q3 25 | $8.3B | $2.1B | ||
| Q2 25 | $8.2B | $2.1B | ||
| Q1 25 | $7.9B | $2.0B | ||
| Q4 24 | $7.5B | $2.0B | ||
| Q3 24 | $7.7B | $2.0B | ||
| Q2 24 | $7.3B | $2.0B | ||
| Q1 24 | $7.2B | $2.0B |
总资产ALRGEN
| Q4 25 | $32.9B | $2.9B | ||
| Q3 25 | $33.4B | $2.9B | ||
| Q2 25 | $33.3B | $2.9B | ||
| Q1 25 | $32.4B | $2.9B | ||
| Q4 24 | $32.3B | $2.8B | ||
| Q3 24 | $32.2B | $2.8B | ||
| Q2 24 | $31.0B | $2.9B | ||
| Q1 24 | $30.9B | $2.8B |
负债/权益比ALRGEN
| Q4 25 | 2.33× | 0.26× | ||
| Q3 25 | 2.42× | 0.26× | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.68× | 0.27× | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | 2.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $414.1M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $342.1M | $17.6M |
| 自由现金流率自由现金流/营收 | 242.9% | 8.9% |
| 资本支出强度资本支出/营收 | 51.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 2.29× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $1.5B | $93.9M |
8季度趋势，按日历期对齐
经营现金流ALRGEN
| Q4 25 | $414.1M | $25.7M | ||
| Q3 25 | $458.6M | $48.1M | ||
| Q2 25 | $473.6M | $28.6M | ||
| Q1 25 | $388.3M | $15.0M | ||
| Q4 24 | $430.0M | $39.2M | ||
| Q3 24 | $461.9M | $49.3M | ||
| Q2 24 | $413.8M | $42.2M | ||
| Q1 24 | $371.3M | $44.7M |
自由现金流ALRGEN
| Q4 25 | $342.1M | $17.6M | ||
| Q3 25 | $412.3M | $43.4M | ||
| Q2 25 | $427.1M | $21.5M | ||
| Q1 25 | $315.5M | $11.4M | ||
| Q4 24 | $326.8M | $33.6M | ||
| Q3 24 | $369.8M | $42.3M | ||
| Q2 24 | $346.4M | $37.4M | ||
| Q1 24 | $246.8M | $36.4M |
自由现金流率ALRGEN
| Q4 25 | 242.9% | 8.9% | ||
| Q3 25 | 926.6% | 23.0% | ||
| Q2 25 | 806.0% | 11.8% | ||
| Q1 25 | 339.5% | 6.8% | ||
| Q4 24 | 441.8% | 19.3% | ||
| Q3 24 | 569.1% | 27.3% | ||
| Q2 24 | 599.5% | 24.3% | ||
| Q1 24 | 503.8% | 24.0% |
资本支出强度ALRGEN
| Q4 25 | 51.1% | 4.1% | ||
| Q3 25 | 104.1% | 2.5% | ||
| Q2 25 | 87.8% | 3.9% | ||
| Q1 25 | 78.4% | 2.1% | ||
| Q4 24 | 139.6% | 3.2% | ||
| Q3 24 | 141.7% | 4.5% | ||
| Q2 24 | 116.7% | 3.1% | ||
| Q1 24 | 254.3% | 5.5% |
现金转化率ALRGEN
| Q4 25 | 2.29× | 1.93× | ||
| Q3 25 | 3.13× | 3.23× | ||
| Q2 25 | 1.23× | 1.92× | ||
| Q1 25 | 1.03× | 2.57× | ||
| Q4 24 | 3.81× | — | ||
| Q3 24 | 4.44× | — | ||
| Q2 24 | 4.02× | 12.70× | ||
| Q1 24 | 3.44× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
